letrozole,abemaciclib,anastrozole
eli lilly,novartis
['monarch 3', 'abema', 'abemaciclib', 'breast', 'lillypad']
at the ongoing 2022, presented the interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with hr+, her2-advanced breast cancer from the monarch 3 study. learn more: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry